Received Apr 29, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| PNC20 | PNEUMO (PREVNAR20) | PFIZER\WYETH | 1 | LC5483 | — |
Patient has minimal fibrosis, was found not to be cancer; interstitial pneumonia; Dry heaving; scratchy throat; hives; This is a spontaneous report received from a Consumer or other non HCP from medical information team. A 21-year-old male patient received pneumococcal 20-val conj vac (dipht CRM197 protein) (PREVNAR 20), in Mar2025 as dose 1, 0.5 ml single (Lot number: LC5483) at the age of 21 years for immunisation. The patient's relevant medical history included: "auto inflammation immune dysregulation" (unspecified if ongoing); "immunodeficiency" (unspecified if ongoing); "allergies to eggs" (unspecified if ongoing); "allergies to a lot of medications" (unspecified if ongoing); "wound", start date: 2023 (unspecified if ongoing), notes: He has wound that has not healed in 3 years.; "Eosinophilic disorder, esophagitis" (unspecified if ongoing); "Eosinophilic disorder, gastritis" (unspecified if ongoing); "immunocompromised" (unspecified if ongoing); "Eosinophilia primary immunodeficiency diagnosis" (unspecified if ongoing). The patient's family history included: "JAK1 mutation", start date: 2021 (unspecified if ongoing). The patient's concomitant medications were not reported. The following information was reported: RETCHING (non-serious) with onset Mar2025, outcome "unknown", described as "Dry heaving"; URTICARIA (non-serious) with onset Mar2025, outcome "unknown", described as "hives"; THROAT IRRITATION (non-serious) with onset Mar2025, outcome "unknown", described as "scratchy throat"; INTERSTITIAL LUNG DISEASE (medically significant) with onset 15Jun2025, outcome "recovered" (Jun2025), described as "interstitial pneumonia"; FIBROSIS (non-serious), outcome "unknown", described as "Patient has minimal fibrosis, was found not to be cancer". The events "dry heaving", "scratchy throat" and "hives" required emergency room visit. The patient underwent the following laboratory tests and procedures: Blood immunoglobulin G: (2025) almost normal, notes: total igg not igg sub class, there is significant point difference in the 2; Chest X-ray: (2025) diffuse interstitial markings in his lungs., notes: Later did x-rays to make sure it actually did go away because, it is not typical pneumonia; (Jun2025) interstitial pneumonia; igg 1: (2025) 290, notes: range; (2025) less than 2, notes: which is considered existentially non existent; (2025) extremely elevated. Therapeutic measures were not taken as a result of interstitial lung disease. Therapeutic measures were taken as a result of retching, throat irritation, urticaria. Clinical course: The case concerned a male patient whose mother, acting as caregiver and legal medical guardian, contacted the company following a call that had been transferred from agency. The caller requested medical information regarding whether interstitial pneumonia experienced by the patient could have been related to PREVNAR 20, which the patient had received in Mar2025. The mother reported that the patient had received PREVNAR 20. Immediately after vaccination, within minutes, the patient reportedly developed hives, dry heaving, and a scratchy throat. He was taken directly to the emergency room, where he was monitored to rule out anaphylaxis and may have received diphenhydramine. The patient did not progress to full anaphylaxis. The mother stated that this immediate reaction had been previously reported to Pfizer in February or Mar2025. Approximately three months after vaccination, in Jun2025, the patient reportedly developed interstitial pneumonia, a condition he had never experienced previously. The patient was taken to the emergency room on three separate occasions due to persistent symptoms. On the third visit, lung imaging was performed, which showed diffuse interstitial markings, leading to the diagnosis of interstitial pneumonia. The condition was presumed to be viral in etiology, and no specific treatment was provided. The patient was not hospitalized. His symptoms resolved over approximately two weeks, and follow-up imaging was conducted to confirm improvement, as the presentation was described as atypical for pneumonia. During follow-up, the patient was noted to have minimal pulmonary fibrosis, which was evaluated and determined not to be malignant. This finding was reported as part of the clinical follow-up and not as a separate adverse event. In Dec2025, the patient was found to have a JAK1 mutation, described as a variant of unknown significance. Treating physicians considered that the mutation could represent a gain-of-function due to the patient's clinical presentation, which included autoinflammation, immune dysregulation, eosinophilia, and features of primary immunodeficiency. Additional medical history reported for the patient included abnormal IgG subclass levels, eosinophilic disorder, esophagitis, gastritis, a chronic non-healing wound present for approximately three years, and multiple medication allergies. The patient was known to have an egg allergy, which prompted the mother to inquire whether PREVNAR 20 contained eggs; she later learned that the vaccine does not contain egg products. The patient had not previously received a pneumococcal vaccine and had discontinued influenza vaccination after the egg allergy was identified. The mother reported that she had been reviewing the patient's medical records and became concerned that there was no documented emergency action plan for future healthcare visits. She questioned whether the temporal association between PREVNAR 20 vaccination and the subsequent interstitial pneumonia could represent a vaccine-related reaction, citing the patient's underlying immune condition as a possible contributing factor. The reporter also provided additional background information about herself, stating that she had been diagnosed with the same JAK1 mutation in 2021. She reported that she had previously received a tetanus vaccination and subsequently developed cellulitis, which she believed could be related to the JAK1 mutation. She emphasized that this personal experience was shared for context regarding potential genetic susceptibility to vaccine reactions and was not related to the patient's adverse events. The medical information request specifically asked whether interstitial pneumonia could represent another reaction associated with PREVNAR 20 remaining in the patient's system.
Medical History/Concurrent Conditions: Autoimmune disorder; Drug allergy; Egg allergy; Eosinophilic esophagitis; Eosinophilic gastritis; Gene mutation; Immunocompromised; Immunodeficiency; Primary immunodeficiency syndrome; Wound (He has wound that has not healed in 3 years.)
Test Date: 2025; Test Name: igg; Result Unstructured Data: Test Result:almost normal; Comments: total igg not igg sub class, there is significant point difference in the 2; Test Date: 2025; Test Name: x-rayed his lungs; Result Unstructured Data: Test Result:diffuse interstitial markings in his lungs.; Comments: Later did x-rays to make sure it actually did go away because, it is not typical pneumonia.; Test Date: 202506; Test Name: x-rayed his lungs; Result Unstructured Data: Test Result:interstitial pneumonia; Test Date: 2025; Test Name: igg 1; Result Unstructured Data: Test Result:290; Comments: range; Test Date: 2025; Test Name: Igg 2; Result Unstructured Data: Test Result:less than 2; Comments: which is considered existentially non existent; Test Date: 2025; Test Name: igg 4i; Result Unstructured Data: Test Result:extremely elevated